<DOC>
	<DOCNO>NCT02882126</DOCNO>
	<brief_summary>This multicenter , open-label trial evaluate safety continue therapy subcutaneous Remodulin® subject pulmonary arterial hypertension ( PAH ) complete CVT-CV-003 study . The study include 50 subject 10 clinical trial center China complete required assessment CVT-CV-003 study . Study visit data collection occur month 6 12 yearly visit beyond 12 month study discontinue sponsor .</brief_summary>
	<brief_title>An Open Label Extension Study Evaluate Safety Continued Therapy Subcutanous Remodulin® Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . The subject voluntarily give write informed consent participate study . 2 . The subject participate complete study CVTCV003 . 3 . Sexually active woman childbearing potential must practice true abstinence intercourse line prefer usual lifestyle , use two different form highly effective contraception . Medically acceptable form effective contraception include : ( 1 ) approve hormonal contraceptive ( birth control pill ) , ( 2 ) barrier method ( condom diaphragm ) use spermicide , ( 3 ) intrauterine device ( IUD ) , ( 4 ) partner vasectomy . Women child bear potential include female experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal ( define amenorrhea least 12 consecutive month ) . Males participate study must use condom length study , least 48 hour discontinue study medication . 4 . The subject develop concurrent illness condition conduct previous study ( include restrict , sleep apnea , chronic renal insufficiency , anemia , uncontrolled systemic hypertension leave sided heart disease ) would make participation study detrimental subject 's health opinion Investigator . 5 . In opinion Principal Investigator , subject able communicate effectively study personnel , consider reliable , willing likely cooperative protocol requirement , include attend study visit , mentally physically capable administer Remodulin continuous SC infusion use micro infusion pump . A subject eligible inclusion study follow criterion apply : 1 . The subject permanently discontinue Remodulin study CVTCV003 . 2 . The subject pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PAH</keyword>
	<keyword>Subcutaneous Treprostinil</keyword>
	<keyword>Remodulin</keyword>
	<keyword>6 Minute Walk Test</keyword>
</DOC>